Testing effectiveness (Phase 2)Study completedNCT01250119
What this trial is testing
Assess the Incidence of EGFR Mutation in Patients With Newly Diagnosed Locally Advanced or Metastatic Non-Small Cell Lung Cancer in the UK, And of Tarceva (Erlotinib) as First-Line Therapy in EGFR Mutation Positive Patients.
Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 688